Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director departure
Appointed director
Skye Bioscience, Inc. (NMUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT NO. 1 TO THE SKYE BIOSCIENCE, INC."
10/03/2023 PRE 14C Form PRE 14C - Other preliminary information statements:
08/22/2023 4 Schwab Andrew J. (10% Owner) has filed a Form 4 on Skye Bioscience, Inc.
Txns: Granted 267,602,039 shares @ $0
Granted 10,558,878 shares @ $0
Granted 684,361,447 shares @ $0.0103, valued at $7M
Granted 161,944,872 shares @ $0.0103, valued at $1.7M
Granted 6,389,921 shares @ $0.0103, valued at $65.8k
Granted 426,348,120 warrants @ $0.0206, valued at $8.8M
08/22/2023 3 Schwab Andrew J. (10% Owner) has filed a Form 3 on Skye Bioscience, Inc.
08/22/2023 3 Grayson Paul A. (Director) has filed a Form 3 on Skye Bioscience, Inc.
08/21/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURED CONVERTIBLE PROMISSORY NOTE",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURITIES PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT",
"SKYE BIOSCIENCE, INC. SECURED NOTE AND WARRANT PURCHASE AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/17/2023 4 Emerald Health Sciences Inc. (10% Owner) has filed a Form 4 on Skye Bioscience, Inc.
Txns: Granted 16,641,486 shares @ $0.017, valued at $282.9k
Granted 41,379,164 shares @ $0.0386, valued at $1.6M
Acquired 9,141,486 warrants @ $0.151, valued at $1.4M
Disposed/sold 9,141,486 warrants @ $0.017, valued at $155.4k
Bought 2,500,000 options to buy @ $0.0386, valued at $96.5k
Disposed/sold 2,500,000 options to buy @ $0.0386, valued at $96.5k
02/23/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "MASTER TRANSACTION AGREEMENT"
01/09/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
01/09/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/09/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/09/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/06/2023 4 TYLE PRAVEEN (Director) has filed a Form 4 on Skye Bioscience, Inc.
Txns: Granted 250,000 options to buy @ $0.017, valued at $4.3k
01/06/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "AMENDMENT NO. 5 MULTI DRAW CREDIT AGREEMENT"
12/16/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/15/2022 3/A Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
11/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/15/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/03/2022 8-K Quarterly results
09/01/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/31/2022 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
07/20/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/06/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy